From discovery to clinic
Cytiva has acquired Precision NanoSystems, a Vancouver, Canada-based global leader in technologies, solutions, and services to support nanomedicine development for genomic medicine applications, including mRNA vaccines and therapeutics.
Accelerate your pipeline with rationally designed LNP formulations to validate active pharmaceutical ingredients (API). We offer an easily accessible and well-characterized lipid nanoparticle portfolio and nanomedicine formulation technologies for mRNA vaccines and future RNA-based therapeutics.
-
Pre-optimized LNP formulations
Speed up RNA-LNP drug development with optimized LNP formulations and advanced LNP technology.
-
A library of lipids
Screen and optimize lipids with custom, GLP, and GMP lipids to ensure efficient encapsulation.
-
Optimize LNP formulations
Because lipid nanoparticles affect RNA-LNP drug and vaccine delivery, potency, and biodistribution.
-
Lipid nanoparticle portfolio FAQs
Accelerate screening with a portfolio of ionizable lipids compositions, and formulation services.
Fit-for-purpose lipid portfolio
Ionizable lipids can shift charge with pH changes to ensure strong binding of nucleic acids during LNP formulation while keeping a neutral charge under physiological pH. They enable efficient cellular delivery and overcome payload size limitations. An LNP portfolio with an array of ionizable cationic lipids allows for optimization.
Accelerate drug development
Our end-to-end genomic medicine tool kit provides access to ionizable lipid mixes through the lipid nanoparticle portfolio, LNP technologies, and deep expertise, to establish robust in-house strategies and infrastructure. This results in a sustainable LNP formulation and manufacturing framework to accelerate drug candidates.
